Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - nadroparin calcium, quantity: 15200 anti-xa iu - injection, solution - excipient ingredients: calcium hydroxide; water for injections - treatment of deep vein thrombosis.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - nadroparin calcium, quantity: 19000 anti-xa iu - injection, solution - excipient ingredients: calcium hydroxide; water for injections - treatment of deep vein thrombosis.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - nadroparin calcium, quantity: 9500 anti-xa iu - injection, solution - excipient ingredients: calcium hydroxide; water for injections - prophylaxis against deep vein thrombosis (dvt) associated with general or orthopaedic surgery. treatment of dvt. prevention of clotting during haemodialysis. prophylaxis of venous thromboembolism in high-risk medical patients who are immobilised due to acute illness or hospitalised in an intensive care unit.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - nadroparin calcium, quantity: 7600 anti-xa iu - injection, solution - excipient ingredients: calcium hydroxide; water for injections - prophylaxis against deep vein thrombosis (dvt) associated with general or orthopaedic surgery. treatment of dvt. prevention of clotting during haemodialysis. prophylaxis of venous thromboembolism in high-risk medical patients who are immobilised due to acute illness or hospitalised in an intensive care unit.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - nadroparin calcium, quantity: 5700 anti-xa iu - injection, solution - excipient ingredients: calcium hydroxide; water for injections - prophylaxis against deep vein thrombosis (dvt) associated with general or orthopaedic surgery. treatment of dvt. prevention of clotting during haemodialysis. prophylaxis of venous thromboembolism in high-risk medical patients who are immobilised due to acute illness or hospitalised in an intensive care unit.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - nadroparin calcium, quantity: 3800 anti-xa iu - injection, solution - excipient ingredients: calcium hydroxide; water for injections - prophylaxis against deep vein thrombosis (dvt) associated with general or orthopaedic surgery. treatment of dvt. prevention of clotting during haemodialysis. prophylaxis of venous thromboembolism in high-risk medical patients who are immobilised due to acute illness or hospitalised in an intensive care unit.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - nadroparin calcium, quantity: 2850 anti-xa iu - injection, solution - excipient ingredients: calcium hydroxide; water for injections - prophylaxis against deep vein thrombosis (dvt) associated with general or orthopaedic surgery. treatment of dvt. prevention of clotting during haemodialysis. prophylaxis of venous thromboembolism in high-risk medical patients who are immobilised due to acute illness or hospitalised in an intensive care unit.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - nadroparin calcium, quantity: 1900 anti-xa iu - injection, solution - excipient ingredients: calcium hydroxide; water for injections - prophylaxis against deep vein thrombosis (dvt) associated with general or orthopaedic surgery. treatment of dvt. prevention of clotting during haemodialysis. prophylaxis of venous thromboembolism in high-risk medical patients who are immobilised due to acute illness or hospitalised in an intensive care unit.

Malta - English - Medicines Authority

florealis ehf. síðumúla 25, 108 reykjavík, iceland - dry extract, of agnus, castus fruit - film-coated tablet - dry extract of agnus castus fruit 4 mg - other gynecologicals

Israel - English - Ministry of Health

gilead sciences israel ltd - anti-cd19 car t cells - dispersion for infusion - anti-cd19 car t cells - acute lymphoblastic leukaemia tecartus is indicated for the treatment of adult patients with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).mantle cell lymphoma tecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton's tyrosine kinase (btk) inhibitor unless ineligible to btk inhibitor •limitation of use : tecartus is not indicated for the treatment of patients with active central nervous system lymphoma